



Organizational update - New board member and new CFO

Stockholm – 1 June 2020.

Kirsti Gjellan is new board member of OxThera as of 19 May 2020.

“It is my pleasure to welcome Kirsti to the board of OxThera”, said Dr. Georges Gemayel, Chairman of OxThera. “Her deep biologic manufacturing experience and successful track record of business leadership over her career will be of important value to OxThera in its development of Oxabact for treating Primary hyperoxaluria.”

“I am honored to join OxThera”, says Kirsti Gjellan. “I believe the company is poised to make a real difference in patients suffering from this devastating rare disease. I am excited to share my insights with the OxThera Board and its management team to help the company deliver on the promise of this new therapy.”

Kirsti has a PhD in Pharmaceutical Technology with over 30 years of experience culminating with senior executive roles in, Development, Quality and Manufacturing at Astra Zeneca, Pfizer and most recently at Sobi where she led global biologics manufacturing and development operations. Kirsti is also a member of the board of directors at Bio-Works Technologies AB.

Mats-Olof Wallin has been appointed new CFO of OxThera as of 1 June 2020. Former CFO Hugo Petit will leave the company for a new assignment outside OxThera.

“I am very pleased that Mats-Olof has joined the company. He has a long and successful track record as CFO from several listed companies in the life science sector.” said Matthew Gantz.

“I would also like to thank Hugo Petit for his contributions and hard work in developing OxThera and wish him the best of luck in his future endeavors” said Matthew Gantz.

Mats-Olof has previously been CFO in several listed companies such as Karo Pharma, Sobi and Biotage.

For further information, please contact:

Matthew Gantz, CEO

Phone: +14846803001

E-mail: matthew.gantz@oxthera.com

About OxThera

OxThera AB is a Swedish biotech company developing a new treatment for primary hyperoxaluria (PH) - a rare genetic and devastating disease with fatal outcomes. Currently pharmaceutical treatment is not available and median age of death is 30, if patients are not transplanted. A phase 3 study and a follow-up, extension study of OxThera's investigational drug candidate Oxabact are ongoing in patients with PH Type I-, II- and III- patients with maintained renal function. Oxabact has received orphan drug designation in the US and the EU for the treatment of PH.